Pharmena Dividend per Share

What does Pharmena do? Pharmena SA develops and markets products based on 1-MNA, a patented physiological active substance. The company sells Dermena for hair loss, Dermena Plus for dandruff and hair loss, Accos for acne, Allerco for hypo-allergic body care, Thermi for burn and sunburn relief, and Revium for anti-wrinkle treatments. Pharmena collaborates with research centers in Europe, the US, and Canada on multidirectional studies. The company has a wholly owned subsidiary, Cortria Corporation, in the US, and its main shareholder is Pelion SA, with Polska Grupa Farmaceutyczna SA holding a 43.65% stake as of 2011. Pharmena SA's revenue comes from direct sales of its product lines to consumers and healthcare providers. Dermena and Dermena Plus target individuals with hair loss concerns, while Accos and Allerco appeal to those seeking acne and sensitive skin solutions. Thermi serves patients recovering from burns, and Revium attracts customers focused on anti-aging skincare. The company’s research partnerships with European, US, and Canadian institutions support product development and market positioning. The company operates through its subsidiary Cortria Corporation in the US, expanding its market reach. Polska Grupa Farmaceutyczna SA, a significant shareholder, likely influences strategic decisions. Pharmena’s product portfolio is structured around specific health and beauty segments, with Dermena and Revium targeting cosmetic and dermatological needs, and Thermi addressing medical recovery applications. Pharmena is one of the most popular companies on Eulerpool.